Lifitegrast (trade name Xiidra) is an FDA approved drug indicated for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis sicca. Lifitegrast reduces inflammation by inhibiting inflammatory cell binding. It is often used in conjunction with ciclosporin (Ikervis or Restasis) for dry eye treatment including meibomian gland dysfunction and inflammatory dry eye. Pharmacology Lifitegrast is supplied as an eye drop and typically applied two times a day .
Lifitegrast , sold under the brand name Xiidra, is a medication for the treatment of signs and symptoms of dry eye, a syndrome called keratoconjunctivitis sicca. Lifitegrast reduces inflammation by inhibiting inflammatory cell binding. It is often used in conjunction with ciclosporin (Ikervis or Restasis) for dry eye treatment including meibomian gland dysfunction and inflammatory dry eye. Pharmacology Lifitegrast is supplied as an eye drop .
R
(trade name Xiidra) is an FDA approved drug indicated
, sold under the brand name Xiidra, is a medication
D
and typically applied two times a day